NCIt definition : An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma
kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to
and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M
known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors.
The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits
tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor
superfamily and plays an important role in nervous system development. ALK dysregulation
and gene rearrangements are associated with a series of tumors.;
UNII : LIJ4CT1Z3Y;
InChIKey : KDGFLJKFZUIJMX-UHFFFAOYSA-N;
CAS number : 1256580-46-7;
Drug name : Alecensa;
Molecule name : RO 5424802; AF-802; AF 802; RO-5424802; CH-5424802; CH 5424802; RG-7853; RG 7853;